JBUON 2017; 22(4): 1022-1031 ISSN: 1107-0625, online ISSN: 2241-6293 • www.jbuon.com E-mail:
[email protected] ORIGINAL ARTICLE Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL) Georgios Boutsikas1, Evangelos Terpos2, Athanasios Markopoulos3, Athanasios Papatheo- dorou4, Angeliki Stefanou3, George Georgiou1, Zacharoula Galani1, Veroniki Komninaka1, Vasileios Telonis1, Ioannis Anagnostopoulos5, Lila Dimitrakopoulou5, Konstantinos An- argyrou6, Konstantinos Tsionos6, Dimitrios Christoulas6, Maria Gonianaki6, Theophanis Giannikos1, Styliani Kokoris7, Kostas Konstantopoulos1, John Meletis1, Maria K. Angelo- 1 7 1 poulou , Anthi Travlou , Theodoros P. Vassilakopoulos 1Department of Hematology, National and Kapodistrian University of Athens; 2Department of Clinical Therapeutics, National and Kapodistrian University of Athens; 31st Propaedeutic Department of Internal Medicine, National and Kapodistrian Universi- ty of Athens; 4Department of Biomedical Research, 251 Air Force General Hospital of Athens; 5Immunology Laboratory, Laikon General Hospital of Athens; 6Department of Hematology, 251 Air Force General Hospital of Athens; 7Hematology Laboratory, National and Kapodistrian University of Athens, Athens, Greece Summary Purpose: The role of Protein Z (PZ) in conditions, such as PZ levels at diagnosis were associated with presence of B thrombosis, inflammation or cancer, is under investigation. symptoms and positive final positron emission tomography Plasminogen Activator Inhibitor-1 (PAI-1) is an acute phase (PET) and higher baseline PAI-1 levels with positive final reactant that promotes thrombosis and tumorigenesis. Sub- PET, too. PZ had a declining trend, but PAI-1 increased ini- ject of this work was to study PZ and PAI-1 in patients with tially and decreased thereafter, during the treatment period.